dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Oza, Amit M. |
dc.contributor.author | Lorusso, Domenica |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Dean, Andrew |
dc.contributor.author | Colombo, Nicoletta |
dc.contributor.author | Aghajanian, Carol |
dc.date.accessioned | 2021-09-23T11:11:58Z |
dc.date.available | 2021-09-23T11:11:58Z |
dc.date.issued | 2020-10-01 |
dc.identifier.citation | Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2020 Oct 1;159:101–11. |
dc.identifier.issn | 0090-8258 |
dc.identifier.uri | https://hdl.handle.net/11351/6347 |
dc.description | Pacients d'edat avançada; Càncer d'ovaris; Inhibidor de la PARP |
dc.description.sponsorship | The study was funded by Clovis Oncology , Inc. Medical writing and editorial support were provided by Jeremy Kennard, PhD, and Frederique H. Evans, MBS, of Ashfield Healthcare Communications. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Gynecologic Oncology;159 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Ovaris - Càncer |
dc.subject | Medicaments antineoplàstics - Ús terapèutic - Eficàcia |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ygyno.2020.05.045 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.1016/j.ygyno.2020.05.045 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Colombo N] Gynecologic Cancer Program, University of Milan-Bicocca and European Institute of Oncology IRCCS, via Ripamonti 435, 20146 Milan, Italy. [Oza AM] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON, Canada. [Lorusso D] Gynecologic Oncology Unit, Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. [Aghajanian C] Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dean A] Department of Medical Oncology, St John of God Hospital Subiaco, 12 Salvado Rd, Subiaco, WA 6008, Australia |
dc.identifier.pmid | 32861537 |
dc.identifier.wos | 000576604900018 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |